Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Shares Purchased by BML Capital Management LLC

BML Capital Management LLC increased its stake in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) by 62.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 442,352 shares of the company’s stock after acquiring an additional 169,852 shares during the quarter. Milestone Pharmaceuticals comprises approximately 0.6% of BML Capital Management LLC’s portfolio, making the stock its 23rd largest holding. BML Capital Management LLC owned about 1.32% of Milestone Pharmaceuticals worth $739,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Analyst Upgrades and Downgrades

Several brokerages recently commented on MIST. HC Wainwright reiterated a “buy” rating and set a $25.00 price target on shares of Milestone Pharmaceuticals in a research note on Friday, March 22nd. Piper Sandler dropped their price objective on shares of Milestone Pharmaceuticals from $6.00 to $5.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 5th. Finally, TD Cowen dropped their price objective on shares of Milestone Pharmaceuticals from $17.00 to $9.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 27th.

Milestone Pharmaceuticals Trading Up 4.3 %

NASDAQ MIST opened at $1.70 on Wednesday. The company has a debt-to-equity ratio of 2.97, a quick ratio of 10.11 and a current ratio of 10.11. The firm has a market cap of $90.36 million, a PE ratio of -1.22 and a beta of 1.77. Milestone Pharmaceuticals Inc. has a one year low of $1.33 and a one year high of $4.49. The firm’s fifty day moving average is $1.67 and its two-hundred day moving average is $2.09.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its quarterly earnings data on Thursday, March 21st. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02). Analysts expect that Milestone Pharmaceuticals Inc. will post -1.15 earnings per share for the current year.

Milestone Pharmaceuticals Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.